EMERGING EVIDENCE THAT MAKES A BIG DIFFERENCE
CVD Image
CVD is a Silent Threat to Life Rhythm

Gain profound comprehension of cardiovascular diseases, which encompass a range of conditions affecting the heart and blood vessels.

CV Continuum
From start to stage, explore CV continuum

As a progressive process, CVD begins earlier in life than previously recognized, indicating that it arises over time.1

ASCVD Risk
ASCVD Risk Estimator

10-year risk for ASCVD is categorized as:
Low-risk (>5%),
Borderline risk (5% to 7.4%),
Intermediate risk (7.5% to 19.9%),
High risk (≥20%).2

CVD: cardiovascular disease; CV: cardiovascular; ASCVD: atherosclerotic cardiovascular disease.

References

  1. Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., ... & Stevenson, W. (2006). The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation, 114(25), 2850-2870.
  2. ASCVD Risk Estimator Plus. American College of Cardiology. Available at: https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/.Last accessed at: 5.7.2022.
EMERGING EVIDENCE THAT MAKES A BIG DIFFERENCE
CVD Image
Anniversary of Aspirin 100

The most frequently used drug worldwide with multiple pharmacological actions unified in one single molecule.1

CV Continuum
Dissolution

Enteric-coated aspirin 100 mg/day causes less gastroduodenal damage.2

ASCVD Risk
Guidelines recommendations to aspirin use

Aspirin is considered as a PRIMARY preventive strategy in asymptomatic ASCVD.3

ASCVD: atherosclerotic cardiovascular disease.

References

  1. Werz, O., Stettler, H., Theurer, C., & Seibel, J. (2024). The 125th Anniversary of Aspirin—The Story Continues. Pharmaceuticals, 17(4), 437.
  2. Dammann H, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Alimentary Pharmacology & Therapeutics. 1999;13(8):1109-1114.
  3. Marx N, Federici M, Schütt K, Müller-Wieland D, et.al., ; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192. Erratum in: Eur Heart J. 2023 Dec 21;44(48):5060. doi: 10.1093/eurheartj/ehad774. Erratum in: Eur Heart J. 2024 Feb 16;45(7):518. doi: 10.1093/eurheartj/ehad857. PMID: 37622663.